Senseonics and Beta Bionics have announced that the Eversense 365 continuous glucose monitor (CGM) now works with the iLet Bionic Pancreas. The integration expands CGM compatibility for iLet beyond Dexcom G7, Dexcom G7 15 day, and Libre 3 Plus. The launch follows the companies’ partnership announcement in September and delivers on their planned Q4 2026 timeline.
Eversense 365 provides continuous glucose readings from an implanted sensor that sends glucose data via an external transmitter. The iLet uses CGM data and its adaptive algorithm to make insulin dosing decisions. The system does not require users to count carbohydrates or manually calculate correction boluses. Users announce meals by indicating if they’re eating less, more, or their usual amount at any given mealtime. The algorithm manages all dosing and auto-corrections.
The CGM will also be compatible with Beta Bionics’s upcoming patch pump, Mint, which is expected to launch in the U.S. in the first quarter of 2027. The company has also submitted its new 3D Intelligence algorithm to the FDA, offering three selectable dosing approaches: Original, Optimized, and Conservative. Pending FDA clearance, the updated algorithm is expected to launch as iLet 3D by the end of 2026, with Mint 3D planned alongside the pump’s commercial launch. Senseonics is also developing a new implantable sensor, Freedom, that does not require an external transmitter. The company is conducting its first in-human clinical study. Pending the results, the company is planning a pivotal study in 2027 and targeting a potential commercial launch in 2028.

